A forgotten challenge when treating osteoporosis: Getting patients to take their meds

Joint Bone Spine

Volumn 74, Issue 1, 2007, Pages 7-8

  Lespessailles, Eric ^a  

^a INSERM   (France)

Author keywords

Adherence; Compliance; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; RALOXIFENE;

DISEASE MARKER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFORMATION; EDITORIAL; FOLLOW UP; HUMAN; MEDICAL DOCUMENTATION; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

BONE DENSITY CONSERVATION AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 33846917202     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.05.007     Document Type: Editorial

References (22)

1. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 (2002) 2018-2026
2. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.-Y., et al. Effect of parathyroid hormone (1-34), on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
3. Marie P.J. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. Osteoporos Int 14 Suppl. 3 (2003) S9-S12
4. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J., Spector T., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 350 (2004) 459-468
5. Miller P.D., Mc Clung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 8 (2005) 1315-1322
6. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 349 (2002) 653-661
7. Tosteson A., Grove M., Hammond C., Moncur M., Ray Th., Hebert G., et al. Early discontinuation of treatment for osteoporosis. Am J Med 115 (2003) 209-216
8. Mc Combs J.S., Thiebaud P., Mc Laughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
9. Papaioannou A., Ioannidis G., Adachi J., Sebaldt R., Ferko N., Puglia M., et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14 (2003) 808-813
10. Hamilton B., Mc Coy K., and Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14 (2003) 259-262
11. Cortet B., and Bénichou O. Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis?. Joint Bone Spine 73 (2006) e1-e7
12. Caro J.C., Ishak K.J., Huybrechts K.F., Raggio G., and Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (2004) 1003-1008
13. Simon J.A., Lewieckin E.M., Smith M.E., Petruschke R.A., Wang L., and Palmisano J.J. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label crossover study. Clin Ther 24 (2002) 1871-1886
14. Boccuzzi S.J., Foltz S.H., Omar M.A., and Kahler K.H. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int Suppl. 3 (2005) (oral abstract)
15. Cramer J.A., Amonkar M.M., Hebborn A., and Suppapanya N. Bisphosphonate dosing regimen influences treatment adherence in postmenopausal women. Osteoporos Int Suppl. 3 (2005) (oral abstract)
16. Bart R., Goette S., Hadji P., and Hammerschmidt T. Persistence and compliance with daily and weekly-administered bisphosphonates for osteoporosis treatment in Germany. Osteoporos Int Suppl. 3 (2005) (oral abstract)
17. Delmas P.D., Vrijens B., Roux C., Le-Moigne-Amrani A., Eastell R., Grauer R., et al. A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: The IMPACT Study. J Bone Miner Res Suppl. 2 (2003) S374
18. Chapurlat R.D., and Cummings S.R. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?. Osteoporos Int 13 (2002) 738-744
19. Clowes J.A., Peel N., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomised controlled trial. J Clin Endocrinol Metab 89 (2004) 1117-1123
20. Pickney C.S., and Arnason J.A. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 16 (2005) 1156-1160
21. Serfaty D., Bruhat M.A., Colau J.C., de Reilhac P., de Lignières B., Roger D., et al. Observance du traitement hormonal substitutif de la ménopause: effet d'un programme d'éducation original. L'Etude COMET. Gynécol Obstét Fertil 30 (2002) 374-382
22. Robbins B., Rausch K.J., Garcia R.I., and Prestwood K.M. Multicultural medication adherence: a comparative study. J Gerontol Nurs 30 (2004) 25-32